The Fight Against Cholesterol Heats Up; FDA Panel Considers Drugs from Regeneron, Amgen Next Week

With an FDA advisory panel slated to meet on June 9 to consider the application by of Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) for the cutting-edge cholesterol-lowering drug Praluent, all eyes were fixed on briefing documents released today by regulators. The drug falls in a new class of medicines known as PCSK9 inhibitors. Sanofi and [...]